10x Genomics, Inc. — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2021-11-01

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-01	Class A Common Stock	M	10000	$5.04	Acquired	49100	Direct
2021-11-01	Class A Common Stock	S	300	$160.4750	Disposed	48800	Direct
2021-11-01	Class A Common Stock	S	500	$162.1577	Disposed	48300	Direct
2021-11-01	Class A Common Stock	S	4667	$163.3414	Disposed	43633	Direct
2021-11-01	Class A Common Stock	S	4333	$164.0542	Disposed	39300	Direct
2021-11-01	Class A Common Stock	S	200	$164.9620	Disposed	39100	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-01	Stock Option (right to buy)	$5.04	M	10000	Disposed	2028-11-02	Class A Common Stock (10000)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $160.03 to $160.94. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $161.52 to $162.50. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $162.65 to $163.645. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $163.65 to $164.62. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $164.81 to $165.11. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This option, originally for 600,000 shares, of which 229,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.